



Atty. Dkt. No. 065691-0388

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Christophe de ROMEUF et al.

Title: CYTOKINE PRODUCTION-
INDUCING ANTIBODY

Appl. No.: 10/527,665

Filing Date: 3/11/2005

Examiner: Crowder, Chun

Art Unit: 1644

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(d), before payment of the issue fee.

RELEVANCE OF EACH DOCUMENT

Any document listed on the attached PTO/SB/08 was cited as being relevant during the prosecution of the corresponding International application. A copy of the International Search Report is attached setting forth the portion of each document considered relevant by the examiner. An English-language counterpart of the foreign-language document has not been provided. The absence of a translation or an English-language counterpart document does not relieve the PTO from its duty to consider any submitted document (37 CFR §1.98 and MPEP §609).

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

FEE

A fee in connection with submission of an information disclosure statement under 37 CFR §1.97(d) in the amount of \$180.00 in accordance with 37 CFR §1.17(p) is attached.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check or credit card payment form being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to

03/07/2006 ATRAN1 00000133 10527665

03 FC:1806

180.00 0P

charge the unpaid amount to Deposit Account No. 19-0741. If any extensions of time are needed for timely acceptance of papers submitted herewith, Applicants hereby petition for such extension under 37 C.F.R. §1.136 and authorizes payment of any such extensions fees to Deposit Account No. 19-0741.


Respectfully submitted,

Date March 1, 2006

By 

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5300
Facsimile: (202) 672-5399

Matthew E. Mulkeen
Attorney for Applicants
Registration No. 44,250



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO & TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: March 1, 2006 (use as many sheets as necessary)		Complete if Known	
		Application Number	Unassigned
Sheet 1 of 1		Filing Date	3/11/2005
		First Named Inventor	Christophe de ROMEUF
		Group Art Unit	1644
		Examiner Name	C. Crowder
		Attorney Docket Number	065691-0388

U.S. PATENT APPLICATION DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Application Document		Name of Patentee or Applicant of Cited Document	Filing Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A1	WO	01/77181		BELIARD et al.	10/18/2001		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A2	CROWE, J.S., et al.; <i>Humanized monoclonal antibody CAMPATH-1H: myeloma cell expression of genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell-derived material</i> ; Clin. Exp. Immunol. (1992) 87, 105-110.	
	A3	VIVIER, E., et al.; <i>Signaling function of reconstituted CD16: ζ : γ : receptor complex isoforms</i> ; International Immunology (1992), Vol. 4, No. 11, pp. 1313-1323.	
	A4	ROUARD, H., et al.; <i>Fc Receptors as Targets for Immunotherapy</i> ; Intern. Rev. Immunol. (1997), Vol. 16, pp. 147-185.	
	A5	LUND, J., et al.; <i>A Protein Structural Change in Aglycosylated I_gG3 Correlates with Loss of huFcγR1 and of huFcγR11 Binding and/or Activation</i> ; Molecular Immunol. (1990), Vol. 27, pp. 1145-1153.	
	A6	LEATHERBARROW, R., et al.; <i>Effector Functions of a Monoclonal Aglycosylated Mouse I_gG2_a: Binding and Activation of Complement Component C1 and Interaction with Human Monocyte Fc Receptor</i> ; Molecular Immunol. (1985), Vol. 22, pp. 407-415.	
	A7	JEFFERIS, R., et al.; <i>A Comparative Study of the N-linked Oligosaccharide Structures of Human I_gG Subclass Proteins</i> ; Intern. Biochem J. (1990), 268, pp. 529-537.	
	A8	PAREKH, R.B., et al.; <i>Association of Rheumatoid Arthritis and Primary Osteoarthritis with Changes in the Glycosylation Pattern of Total Serum I_gG</i> ; Nature. (1985), Vol. 316, pp. 452-457.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.